InsiderTrades.com logo
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.

CLYM Insider Trading

Insider Ownership Percentage: 3.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,494.70

Climb Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Climb Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Climb Bio Share Price & Price History

Current Price: $1.95
Price Change: +0.30 (1.20%)
As of 12/20/2024 06:51 PM ET

This chart shows the closing price history over time for CLYM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Most People Are Dead Wrong.
From Brownstone Research   |   Ad
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.
I call it my AI Retirement Playbook. I recommend you check it out now.

Climb Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2024Emily PimblettCAOSell1,235$2.02$2,494.7011,329View SEC Filing Icon  
See Full Table
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.

SEC Filings (Institutional Ownership Changes) for Climb Bio (NASDAQ:CLYM)

69.76% of Climb Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Climb Bio logo
Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.
Read More on Climb Bio

Today's Range

Now: $1.95
Low: $1.86
High: $2.07

50 Day Range

MA: N/A

52 Week Range

Now: $1.95
Low: $1.86
High: $11.55

Volume

1,467,232 shs

Average Volume

445,832 shs

Market Capitalization

$131.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Climb Bio?

Climb Bio's top insider shareholders include:
  1. Emily Pimblett (CAO)
Learn More about top insider investors at Climb Bio.
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.